-- 周三收盘时,澳大利亚股市走势平稳,略微偏向上涨,投资者正在权衡有关美伊第二轮和平谈判的报道。 S&P/ASX 200 指数变化不大,收于 8,978.70 点。 美国总统特朗普表示,未来两天,与伊朗的谈判可能在巴基斯坦恢复,尽管美国对伊朗港口的海上封锁仍在继续。布伦特原油期货价格上涨 1%,至每桶 95.77 美元。 周二,华尔街股市方面,纳斯达克指数上涨近 2%,标普 500 指数上涨 1.2%。 在国内方面,国际货币基金组织(IMF)下调了对澳大利亚的经济增长预期,目前预计2026年澳大利亚国内生产总值(GDP)增长率为2%,低于此前预测的2.1%;2027年为1.7%,低于此前预测的2.2%。 澳新银行(ANZ)在一份报告中指出,预计今年澳大利亚私营部门信贷同比增长7.2%,创下2022年以来的最快增速,之后到2027年底将放缓至同比增长5.7%。 澳大利亚国民银行(NAB)的消费者支出趋势报告显示,受油价上涨导致燃油支出大幅增长的推动,澳大利亚3月份消费者支出环比增长2.1%。 公司新闻方面,维珍澳大利亚控股公司(ASX:VGN)表示,其2026财年财务预期保持不变,预计下半年息税前利润(EBIT)和息税前利润率将高于上年同期。该公司股价收盘上涨7%。 Mesoblast(ASX:MSB)获得了一项专利嵌合抗原受体技术平台的独家许可,旨在提升其产品的功效。该公司股价收盘上涨7%。 最后,兖煤澳大利亚公司(ASX:YAL)宣布,已与EMR Capital Advisors、Kestrel Coal(EMR)、Adaro Capital和EMR Capital Management签署具有约束力的交易文件,拟以最高24亿澳元的价格收购Kestrel Coal Group。Kestrel Coal Group持有昆士兰州Kestrel煤矿合资企业80%的股份。该公司股价收盘下跌2%。
Related Articles
Scotiabank Previews This Week's February and Preliminary March GDP for Canada
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%